Russell Investments Group Ltd. Boosts Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Russell Investments Group Ltd. raised its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 5.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,895 shares of the company’s stock after buying an additional 2,038 shares during the quarter. Russell Investments Group Ltd.’s holdings in Medpace were worth $12,237,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. RiverPark Advisors LLC purchased a new position in shares of Medpace in the fourth quarter valued at $26,000. Contravisory Investment Management Inc. purchased a new stake in Medpace during the fourth quarter valued at approximately $26,000. FinTrust Capital Advisors LLC bought a new stake in shares of Medpace in the 3rd quarter valued at approximately $30,000. GAMMA Investing LLC bought a new position in shares of Medpace during the 4th quarter valued at approximately $30,000. Finally, McGlone Suttner Wealth Management Inc. bought a new position in Medpace during the fourth quarter valued at $33,000. Institutional investors own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

MEDP has been the topic of several recent analyst reports. Guggenheim increased their price target on Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and boosted their target price for the company from $340.00 to $450.00 in a research note on Tuesday, April 23rd. UBS Group upgraded shares of Medpace from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $282.00 to $452.00 in a report on Thursday, February 15th. Deutsche Bank Aktiengesellschaft started coverage on shares of Medpace in a research report on Monday, March 18th. They set a “hold” rating and a $395.00 target price on the stock. Finally, Robert W. Baird boosted their price target on Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $443.00.

Insider Activity at Medpace

In other news, major shareholder Medpace Investors, Llc sold 13,988 shares of the business’s stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $386.39, for a total transaction of $5,404,823.32. Following the sale, the insider now owns 5,525,959 shares in the company, valued at $2,135,175,298.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Medpace news, CEO August J. Troendle sold 100,000 shares of Medpace stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the sale, the chief executive officer now owns 4,833,019 shares of the company’s stock, valued at approximately $1,995,940,186.62. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Medpace Investors, Llc sold 13,988 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $386.39, for a total value of $5,404,823.32. Following the sale, the insider now owns 5,525,959 shares in the company, valued at approximately $2,135,175,298.01. The disclosure for this sale can be found here. Insiders have sold 204,442 shares of company stock valued at $82,702,867 in the last ninety days. Corporate insiders own 20.30% of the company’s stock.

Medpace Trading Up 0.4 %

MEDP opened at $392.57 on Friday. Medpace Holdings, Inc. has a 12 month low of $197.39 and a 12 month high of $421.00. The stock has a fifty day moving average price of $398.08 and a 200-day moving average price of $331.07. The firm has a market cap of $12.16 billion, a price-to-earnings ratio of 40.02, a PEG ratio of 1.95 and a beta of 1.40.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The firm had revenue of $511.00 million for the quarter, compared to the consensus estimate of $512.39 million. During the same quarter in the previous year, the firm earned $2.27 EPS. The company’s quarterly revenue was up 17.7% compared to the same quarter last year. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 11.23 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.